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Resumo 
 
 
  
 
Este estudo avaliou se o tratamento de ratos diabéticos induzidos com 
estreptozotocina, com insulina ou factor de crescimento derivado da insulina 
(IGF1), em doses que não revertem a hiperglicemia, afectam os sinais 
comportamentais da neuropatia diabética e a ativação neuronal na medula 
espinhal. Foi também avaliada a participação de algumas das principais áreas 
do tronco cerebral (VLPAG), envolvidas na modulação descendente da dor. 
Uma semana após a indução da diabetes, foi iniciado o tratamento dos 
animais, 3 vezes por semana durante 3 semanas, com soro fisiológico, insulina 
(2 IU) ou IGF1 (2,5 mg / Kg). O tratamento com insulina ou IGF1 preveniu 
sinais comportamentais de neuropatia diabética, denominada alodínia 
mecânica. A avaliação comportamental dos animais através do teste de formol 
evidenciou que, quer a insulina quer o IGF1, previnem a elevada frequência de 
espasmos observados nos ratos diabéticos, para valores semelhantes aos dos 
controlos. Quanto à activação nociceptiva da expressão de c-fos no corno 
dorsal da medula espinal, esta foi inibida por ambos os tratamentos. A 
melhoria das acções comportamentais e da activação nociceptiva dos 
neurónios espinhais mediada pelo tratamento com IGF1 é susceptível de ser 
devida aos efeitos na modulação dolorosa descendente proveniente do tronco 
cerebral, mediada pela serotonina e noradrenalina. Ratos diabéticos 
apresentaram elevados números de neurónios imunorreactivos para TpH 
(marcador de neurónios serotoninérgicos) no RVM, ou para TH (marcador de 
neurónios noradrenérgicos) no núcleo celular noradrenérgico A5 (pontine). 
Estes números foram normalizados para níveis controlo, mas apenas quando 
tratados com IGF1, uma vez que a insulina não afecta estes parâmetros. 
Observou-se que os níveis de serotonina e noradrenalina na medula espinhal 
estavam aumentados, bem como os ratos tratados com insulina. Estes 
resultados evidenciaram que a insulina e o IGF1 possuem diferentes efeitos no 
sistema nervoso, sendo que os efeitos centrais devem-se essencialmente ao 
IGF1. 
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Abstract 
 
This study evaluates if the treatment of Streptozotocin-induced diabetic rats 
with insulin or insulin growth factor 1 (IGF1), in doses that do not reverse 
hyperglicemia, affect behavioural signs of diabetic neuropathy and neuronal 
activation at the spinal cord. The participation of main brainstem areas involved 
in descending modulation of pain was also evaluated (VLPAG). One week after 
diabetes induction, the animals were injected, 3 times per week, with saline, 
insulin (2 IU) or IGF1 (2.5 mg/Kg) during 3 weeks. Treatment with insulin or 
IGF1 prevented behavioural signs of diabetic neuropathy, namely mechanical 
allodynia. Behavioural evaluation of the animals by the formalin test showed 
that insulin and IGF1 strongly prevented the higher frequency of flinching 
behavior to values similar to controls. Nociceptive activation of c-fos expression 
induced by formalin at the spinal dorsal horn was inhibited by both treatments. 
The improvement of behavioural actions and nociceptive activation of spinal 
neurons mediated by IGF1 treatment are likely to be due to effects in 
descending pain modulation from the brainstem, mediated by serotonin and 
noradrenaline. Diabetic rats presented higher numbers of neurons 
immunoreactive for TpH (marker of serotoninergic neurons) at the 
rostroventromedial medulla or for TH (marker of noradrenergic neurons) at the 
pontine A5 noradrenergic cell group. These numbers were normalized to 
control levels only after IGF1 treatment, but not after insulin. The levels of 
serotonin and noradrenaline at the spinal cord were increased in non treated-
diabetic rats and insulin treated-rats. These results show that insulin and IGF1 
appear to have different effects on the nervous system, with more central 
effects being ascribed to IGF1. 
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Chapter 1: Introduction 
 
1.1 Pain 
1.1.1 General Considerations 
The International Association for the Study of Pain (IASP) defines pain as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage”. Pain progression is characterized by 
“sensory-cognitive-affective-illness behavior” (Pearce, 2005). From the moment that a 
nociceptive stimulus is applied to the periphery until pain perception occurs, multiple factors 
are recruited, such as cognitive and affective conditions (Fig. 1). Althought pain protects the 
body against potentially damaging stimuli and motivates patients to seek health care, if it 
persists longer than the reasonable expected healing time, it should be considered chronic 
pain. Chronic pain syndrome (CPS) is often a pejorative descriptor and it has been defined as 
chronic anxiety and depression, anger, and changed lifestyle, all with a variable, but 
significant level, of neurologically based pain. Chronic pain is associated with chronic 
pathological processes and its pathophysiology is multifactorial, complex and poorly 
understood (Almeida et al., 2004). 
 
 
From Tracey and Mantyh, 2007 
Fig. 1: Diagram illustrating the factors that influence pain perception. 
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Depending on the type of nociceptive stimulus and the pathways involved, several pain 
syndromes can be defined: nociceptive, inflammatory, dysfunctional and neuropathic pain.  
Nociceptive pain (Fig. 2) occurs in response to noxious stimuli and continues only in its 
presence. It alerts to intense thermal or mechanical stimuli, as well as exogenous and 
endogenous chemical mediators (Dhaka et al., 2006). It is mediated by high-threshold 
unmyelinated C or thinly myelinated Aδ primary sensory neurons that feed into nociceptive 
pathways of the central nervous system (CNS) (Woolf and Ma, 2007). Certain diseases may 
generate recurrent or ongoing noxious stimuli to produce chronic nociceptive pain.  
Inflammatory pain (Fig. 3) is caused by tissue damage and by the subsequent 
inflammatory response. The first lesion and the inflammatory process cause alterations in 
the activities of Aδ and C fibers. These fibers are responsible for sensitization, recruitment of 
nociceptors normally silent and activation of ionic channels and membrane receptors. 
Tipically, inflammatory pain disappears after resolution of the initial tissue injury. However, 
in some situations, chronic pain may persist after inflammation disappears, due to 
permanent changes in the nerve fibers (Michaud et al., 2007; Pace et al., 2006). 
 
Fig. 2: Nociceptive pain. 
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Fig. 3: Inflammatory pain. 
 
 Dysfunctional pain (Fig. 4) is a group of pain syndromes caused by malfunction of the 
somatosensory system. This malfunction can be considered a disease in its own right 
(Costigan et al., 2009). Dysfunctional pain occurs in situations in which there is no 
identifiable noxious stimulus nor any detectable inflammation or damage to the nervous 
system. It is unclear in most cases what causes the manifestation or persistence of 
dysfunctional pain. This type of pain appears to result from an autonomous amplification of 
nociceptive signals inside the CNS (Nielsen et al., 2008) with a disturbed balance of 
excitation and inhibition in central circuits (Julien et al., 2005).  
Neuropathic pain (Fig. 5), the pain state that will be addressed in this Master thesis, is 
defined by the IASP as “pain initiated or caused by a primary lesion or dysfunction in the 
nervous system” (Merskey and Bogduk, 1994). Neuropathic pain is a subcategory of the 
larger group of pain syndromes and can be divided into peripheral and central neuropathic 
pain. The former results from lesions to the peripheral nervous system (PNS) caused by 
metabolic diseases, mechanical trauma, neurotoxins, infection, or tumor invasion (Dworkin 
et al., 2003; Woolf and Mannion, 1999). Central neuropathic pain most commonly results 
From Costigan et al., 2009 
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from spinal cord injury, stroke, or multiple sclerosis (Ducreux et al., 2006). In both cases, the 
primary disease (such diabetes mellitus) and the neural damage it causes are only the 
initiators of a cascade of changes that induce and sustain neuropathic pain. 
 
Fig. 4: Dysfunctional pain. 
 
 
Fig. 5: Neuropathic pain. 
From Costigan et al., 2009 
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1.1.2 Ascending sensory pathways 
 
 
The ascending sensory pathways are the main avenues by which information 
concerning the body’s interaction with the external environment, its internal condition, and 
the position and movement of its parts, reach the brain.  
Anatomically, the ascending sensory systems consist of three distinct pathways 
(Table 1): the anterolateral system (ALS), the dorsal column-medial lemniscal (DCML) 
pathway, and the somatosensory pathways to the cerebellum. The anterolateral system, 
which includes the spinothalamic, spinoreticular, spinomesencephalic, spinotectal, and 
spinohypothalamic tracts, conveys predominantly pain and temperature sensation, as well 
as nondiscriminative touch, pressure, and some proprioceptive sensation. The dorsal 
column medial lemniscal pathway (which includes the fasciculus gracilis, fasciculus 
cuneatus, and medial lemniscus) relays discriminative (fine) tactile sense, vibratory sense, 
and position sense. The somatosensory pathways to the cerebellum, which include the 
anterior, posterior, and rostral spinocerebellar, as well as the cuneocerebellar tracts, relay 
primarily proprioceptive (but also some pain and pressure) information (Patestas and 
Gartner, 2006). 
Table 1: General description of anatomical and functional aspects of the ascending sensory 
pathways. 
 
 
From Patestas and Gartner, 2006 
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The output from the dorsal horn to higher centres in the brain is carried by 
projection neurons located at the spinal cord along ascending pathways. These ascending 
pathways carries primarily sensory information and so provides the sensory component of 
the pain experience (Mello and Dickenson, 2008). 
The anterolateral system (ALS) is the main ascending nociceptive pathway and 
transmits nociceptive, thermal and nondiscriminatory touch information to higher brain 
centers, generally by a sequence of three neurons and interneurons (Fig. 6). The sequence of 
transmission consists of a first order neuron whose cell body is located in the dorsal root 
ganglion and transmits sensory information from peripheral structures to the dorsal horn of 
the spinal cord. These neurons have two main types of fibers: the fast-conducting 
myelinated Aδ fibers and the slow-conducting unmyelinated C fibers. The second order 
neuron has its cell body within the dorsal horn of the spinal cord. Their axons usually 
decussates and ascends in the direct pathway of the ALS (spinothalamic tract) to synapse in 
the contralateral thalamus, and sending some collaterals to the reticular formation (as it 
ascends through the brainstem); in the indirect pathway of the ALS (spinoreticular tract) to 
synapse in the reticular formation, and sending some collaterals to the thalamus; or as 
spinomesencephalic, spinotectal, or spinohypothalamic fibers to synapse in several 
brainstem nuclei. The third order neuron has its cell body in the thalamus, and their axon 
ascends ipsilaterally to terminate in the somatosensory cortex (Patestas and Gartner, 2006). 
 
Approximately 85% of the nociceptive fibers from the spinal cord ascending in the 
ALS, terminate in the brainstem reticular formation. From there, the information eventually 
reaches the thalamus via multiple additional synapses that occur in the brainstem. The 
reticular formation sends fibers transmitting nociceptive input not only to the thalamus but 
also to the hypothalamus, which is associated with the autonomic and reflex responses to 
nociception, and the limbic system, which mediates the emotional component of 
nociception. 
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Adapted from Patestas and Gartner, 2006 
 
Fig. 6: Ascending sensory pathway that transmits nondiscriminative touch, pain, and 
temperature sensations from the body. 
 
1.1.3 Descending nociceptive pathways 
 
Studies that link anatomy and pharmacology of dorsal horn neurons and descending 
facilitatory pathways provided a better understanding of the neuronal plasticity associated 
with a peripheral insult. The supraspinal structures receive and integrate nociceptive 
information to regulate behaviour, and are potential sources of descending influence on 
nociceptive processes. 
Supraspinal control of nociception at the spinal cord originates from many brain 
regions and plays a critical role in determining the experience of both acute and chronic pain 
(Heinricher et al., 2009). This descending control can be inhibitory or facilitatory and 
originate from a number of supraspinal sites like periaqueductal gray matter (PAG), 
parabrachial nucleus, nucleus tractus solitarius, nucleus raphe magnus, rostroventromedial 
medulla (RVM), noradrenergic cell groups (A5, A6 and A7), dorsal reticular nucleus (DRt) and 
ventrolateral medulla (VLM) (Yoshimura and Furue, 2006) (Fig. 7). Under normal conditions, 
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a “balance” is maintained between inhibitory and facilitatory pathways. When the 
equilibrium is disturbed, for example, after a disease like diabetic neuropathy, the excitation 
dominates and, consequently, pain is potentiated in intensity or persistence (Porreca et al., 
2002; Suzuki et al., 2004). 
 
 
From Tracey and Mantyh, 2007 
 
Fig. 7: Descending pain modulatory system. ACC - anterior cingulated cortex; DLPT - 
dorsolateral pontine tegmentum; NCF - nucleus cuneiformis; PAG - periaqueductal gray 
matter; +/- indicates both pro- and anti- nociceptive influences, respectively. 
 
 
1.1.3.1 PAG-RVM system 
The best studied descending pain control is the PAG-RVM system. The 
periaqueductal gray (PAG) area is subdivided in dorsal medial PAG (DMPAG), dorsal lateral 
PAG (DLPAG), lateral PAG (LPAG) and ventrolateral PAG (VLPAG), according to Paxinos and 
Watson (Paxinos and Watson, 2005). The PAG has a key role in descending mechanisms that 
modulate spinal nociceptive activity and is interconnected with the hypothalamus and limbic 
forebrain structures including the amygdala and also receives direct spinomesencephalic 
input (Fields, 2000). The VLPAG plays a crucial role in pain control (Behbehani, 1995). The 
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PAG projects to the RVM, which, in turn, sends output to spinal cord laminae important in 
nociceptive function. The PAG control of dorsal horn responses is highly selective for noxious 
inputs. Understanding the PAG-RVM system is of considerable importance from both a 
behavioral and therapeutic point of view. 
As previously stated, the PAG does not project directly to the spinal cord. Instead, its 
principle descending projection is to the RVM, which can be considered the output of the 
midline pain-modulation system. The RVM includes the serotonin-rich nucleus raphe 
magnus and adjacent reticular formation, and projects diffusely to dorsal horn laminae 
important in nociceptive processing, including the superficial and deep dorsal laminae. It 
also receives dense input of noradrenergic nerve fibers arising from the A1, A2, A5, A6 and 
A7 cells groups (Herbert and Saper, 1992; Kwiat and Basbaum, 1990). 
Fields and Colleagues (1983) have characterized cells in the RVM that may constitute 
the physiological basis for generation of biphasic modulation of spinal nociceptive 
transmission. They have operationally defined three classes of neurons, named “ON-cells”, 
“OFF-cells” and “NEUTRAL-cells”. “ON-cells” are the facilitating outputs from the RVM 
whereas “OFF-cells” function as the antinociceptive output (inhibits nociceptive transmission 
in the spinal dorsal horn). Neutral-cells had no consistent correlated response with behavior 
reactions and could represent a subtype of ON- or OFF-cells (Ellrich et al., 2000).  
It is thought that neutral-cells can be recruited to become ON- or OFF-cells during the 
development of chronic pain states. Manipulations that increase nociceptive responsiveness, 
thus indicating facilitation, also increase ON-cell activity, whereas the opposite occurs with 
OFF-cells which are inhibited by morphine antagonists. These experimental outcomes 
suggest that supraspinal sites can contribute to development or maintenance of exaggerated 
pain behaviors produced by noxious (e.g. hyperalgesic) and non-noxious (e.g. allodynic) 
peripheral stimuli, even in the absence of an obvious pathology (Urban and Gebhart, 1999).  
  
1.1.3.2 Noradrenergic system  
Catecholamines, such as adrenaline and noradrenaline (NA), modulate noxious 
transmission at the spinal dorsal horn. Noradrenergic cell groups involved in pain 
modulation encompasse mainly the A1 to A7 cell groups and are located in the brainstem. 
Although the origin of noradrenaline at the spinal cord is supraspinal, a few spinal neurons, 
mostly near the central canal, also possess NA (Willis and Coggeshall, 2004). 
  
MSc Thesis                                                                     Central effects of insulin and IGF1 in diabetic neuropathy 
 
Liliana Silva                                                                    10
The A1 cell group is located ventrolaterally at the medulla oblongata at the level of 
the area postrema, A2 is distributed throughout the dorsal vagal complex, A3 is in the 
medullary reticular formation, and A4 surrounds the fourth ventricle. The A5 cell group is in 
the ventrolateral pons, A6 (locus coeruleus and nucleus subcoeruleus) is dorsally in the pons 
and A7 is in the lateral part of the pons, close to the lateral lemniscus (Fig. 8). The A5, A6 and 
A7 noradrenergic cell groups have significant descending noradrenergic projections to the 
spinal dorsal horn and are designated as the descending noradrenergic pain inhibitory 
pathway (Fig. 8). Evidence for a relevant role of the A5, A6 and A7 in descending pain 
modulation comes from studies showns that stimulation of those areas induces analgesia, 
which can be blocked by intrathecal administration of α2-adrenoceptors antagonists 
(Pertovaara, 2006). 
At the periphery, the sympathetic system is the main neuronal source of 
noradrenaline (Pertovaara, 2006). Several studies, such as does done by McLahlan et al. 
(1993) and Perl (1999), have demonstrated that NA released from sympathetic nerve 
terminals produces hyperalgesia by acting on the dorsal root ganglion cells and the 
peripheral nerves under pathological conditions such as nerve injury. 
 
From Pertovaara, 2006 
Fig. 8: Location of noradrenergic A5, A6 and A7 cell groups in the pons. 
a) Noradrenaline 
Noradrenaline has been implicated in the modulation of endogenous analgesic 
mechanisms via the descending inhibitory pain pathways in the brain and spinal cord. An 
imbalance in these inhibitory mechanisms may contribute to central sensitization and 
hyperexcitability of the spinal and supraspinal pain transmitting pathways leading to 
RVM 
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persistent pain (Basbaum and Fields, 1984; Clark and Proudfit, 1993; Fields and Basbaum, 
1999; Fields et al., 1991). 
 
Noradrenaline, as other catecholamines dopamine and epinephrine, possesses two 
hydroxyl groups and one amine group bound to a benzene ring. It is biosynthesized from 
tyrosine that is first converted to dihidroxyphenylalaline (DOPA) by tyrosine hydroxylase 
(TH). After that, DOPA is converted to dopamine by aromatic amino acid decarboxylase. In 
noradrenergic cells dopamine is further converted to noradrenaline by dopamine-beta-
hydroxylase (Fig. 9) (Pertovaara, 2006).  
 
From www.rpi.edu/dept/bcbp/molbiochem/BiochSci/sbello/tyr_norep.gif 
Fig. 9: Structure and synthesis of noradrenaline. 
 
Blockade of peripheral noradrenergic receptors by antidepressants may contribute 
to a peripheral analgesic action because, as already mentioned, peripheral release of 
noradrenaline and serotonin is known to be hyperalgesic (Mico et al., 2006). 
(TH) 
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b) Spinal and supraspinal mechanisms of pain modulation 
The source of spinal noradrenaline is descending axons originating in the 
noradrenergic neuronal cell groups of the brainstem (Fig. 10) (Jones, 1991; Proudfit, 1988), 
particularly the locus coeruleus, but also the A5 and A7 noradrenergic cell groups (Kwiat and 
Basbaum, 1992). Stimulation of these noradrenergic cell groups produces spinal release of 
noradrenaline and are connected with other pain control centers that receive projections 
from the PAG (Bajic and Proudfit, 1999). Curiously, the noradrenergic innervation of the 
spinal cord differs according to the rat strain, which was shown to affect descending pain 
modulation (West et al., 1993; Clark and Proudfit, 1992). 
 The distribution of various adrenoceptor types varies with descending pain 
modulation structure (Day et al., 1997; Nicholas et al., 1993; Scheinin et al., 1994; Wang et 
al., 1996) and has a role in pain control. 
 
The spinal dorsal horn is a critical link for all ascending pain pathways and the spinal 
cord receives strong innervation from descending noradrenergic pathways.  
As will be mentioned below, noradrenaline receptors are classically divided into two 
main categories: alpha- and beta-adrenoceptors. Alpha-adrenoceptors are classified into 
subtypes alpha- 1A, 1B, 1D, 2A, 2B and 2C, and beta-adrenoceptors into subtypes beta- 1, 2 
and 3 (Aantaa et al., 1995; Ruffolo and Hieble, 1994). Like 5-HT, NA can variably influence 
nociceptive processing, depending on the mix and subtype of adrenoceptors activated, as 
well as on the presence, duration, and nature of pain. 
 It has been demonstrated that electrical stimulation of the noradrenergic A5, A6 
and A7 cell groups produces antinociceptive effects (Burnett and Gebhart, 1991; Yeomans et 
al., 1992; West et al., 1993; Tsuruoka et al., 2004). These antinociceptive actions involve not 
only direct membrane hyperpolarization and enhancement of inhibitory transmitter release, 
but also reduce the excitatory transmitter release. These presynaptic actions of NA are 
tested in SG that receives inputs predominantly from Aδ and C afferent fibers, which is 
known to carry the nociceptive information (Yoshimura and Furue, 2006). It has 
subsequently been shown that activation of α2-adrenoceptors within the noradrenergic cell 
groups of the brainstem may produce pronociceptive effects in some contitions (Ossipov and 
Gebhart, 1986; Pertovaara et al., 1994), contributing to maintenance of chronic pain and 
  
MSc Thesis                                                                     Central effects of insulin and IGF1 in diabetic neuropathy 
 
Liliana Silva                                                                    13
hyperalgesia (Baron, 2000). Spinal and supraspinal effects of noradrenaline are, therefore, 
likely to be opposite. 
 
Ventrolateral pathways have a major role in mediating descending antinociceptive 
influences from the noradrenergic cell groups. This was shown by the finding that the 
antinociceptive effect induced by locus coeruleus stimulation is blocked by a lesion of the 
ventrolateral part of the spinal cord, but not of the dorsolateral funiculus (Mokha et al., 
1986; Tsuruoka et al., 2004).  
 
 
 
Fig. 10: Summary of the neuronal pathways from the PAG to noradrenergic neurons in the 
A5, A6 and A7 cell groups. STT - spinothalamic tract. 
 
1.1.3.3 Serotoninergic system  
The serotoninergic system has been recognized as one of the main neurotransmitter 
systems participating in pain transmission, processing and controlling. Both pro-nociceptive 
and anti-nociceptive effects have been attributed to serotonin (5-HT) depending on the site 
and the receptor subtype it acts on (Roberts, 1989; Eide and Hole, 1993; Kayser et al., 2010). 
Similar to a noradrenergic system, the descending serotonin containing fibers arise 
from the nucleus raphe magnus (NRM), a nucleus located at the RVM, the main source of 
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serotoninergic fibers in the spinal cord. These fibers innervate almost all brain areas, through 
its ascending and descending projections. Other serotoninergic nuclei, the raphe pallidus 
(RP) and the raphe obscurus (RO), are also within the vicinity of RVM. However, the 
contribution of the latter two nuclei is thought to be small (Millan, 2002; Basbaum et al., 
1984; Ruda et al., 1986 and Ho et al., 1991). 
Like the noradrenergic system, the serotoninergic fibers also descend through the 
dorsolateral funiculus and bifurcate their axon collaterals to innervate dorsal horn neurons, 
in particular lamina I and II, central canal, intermediolateral nucleus, and ventral horn 
(Millan, 2002; Basbaum et al., 1984). Traditionally, actions of 5-HT in the dorsal horn have 
been considered as dedicated to the suppression of nociceptive transmission (Basbaum and 
Fields, 1984; Eide and Hole, 1993), but the role of 5-HT depends on the spinal receptors (see 
bellow). 
a) Serotonin 
Serotonin (5-hydroxytryptamine, 5-HT), a metabolite of the essential amino acid 
tryptophan, has been the subject of intense biological research since the early 1950s. With 
increasing knowledge, it has emerged as a mediator of several functions in the human body, 
including mood, appetite, regulation of gastrointestinal motility and pain modulation 
(Keszthelyi et al., 2009). At the periphery, the action of serotonin is mainly seen as an 
inflammatory mediator that is released from platelets and mast cells after tissue injury, and 
exerts direct actions (excitatory) on C-fibers (Eide and Hole, 1993; Dray, 1995). 
Serotonin is synthesized from tryptophan through hydroxylation and 
decarboxylation. These processes are catalysed by the tryptophan hydroxylase (TpH) and the 
aromatic acid decarboxylase (AADC), respectively (Gershon and Tack, 2007; Lesurtel et al., 
2008) (Fig. 11). Tryptophan hydroxylase (tryptophan 5- monooxygenase) belongs to a 
superfamily of aromatic amino acid hydroxylases, together with phenylalanine (PAH) and 
tyrosine hydroxylases (Fitzpatrick, 1999). Its expression is limited to a few specific cells: 
brainstem neurons, pinealocytes, mast cells, mononuclear leukocytes, intestinal 
enterochromaffin cells and bronchopulmonary neuroendocrine epithelial cells. There are 
two known isoforms of TpH. Tryptophan hydroxylase 1 (TpH1) is localized in 
enterochromaffin cells and the pineal gland and tryptophan hydroxylase 2 (TpH2) is present 
in neurons (Walther et al., 2003). Both isoforms employ molecular oxygen and the cofactor 
tetrahydrobiopterin to convert tryptophan to 5-hydroxytryptophan (5-HTP), which is then 
converted by AADC to serotonin. 
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5-HT is released from the synaptic vesicles to the synaptic space by a Ca
2+
-dependent 
process, while its reuptake from synaptic space to 5-HT neurons is carried out by the 
membrane-bound 5-HT transporter occurring in axons, bodies and/or dendrites of 5-HT 
neurons. 5-HT is catabolized by mitochondrial type A monoamine oxidase (MAO) (Filip and 
Bader, 2009). 
 
 
Fig. 11: Structure and synthesis of serotonin.  
 
5-HT can produce anti-nociceptive and pro-nociceptive effects depending on the 
targetted receptor. More than 15 receptor subtypes have been identified for 5-HT, providing 
it with a diverse repertoire in pain and other responses. It is noteworthy that pain, 
particularly chronic pain, can be accompanied by fear, anxiety, depression, aversion and 
sleep disturbances, which are all underpinned by monoamine-mediated neurotransmission. 
However, this complexity has caused problems in deducing the role of 5-HT in nociception, 
and earlier studies often presented conflicting views on the pro-nociceptive and anti-
nociceptive actions of this transmitter (Millan, 2002). 
Althought the physiological function of 5-HT containing cells in pain modulation has 
been questioned (Gao and Mason, 2000), at least a proportion of “on” cells of the RVM are 
likely to contain 5-HT. Tonic activation of 5-HT-mediated and non-5-HT-mediated brainstem 
facilitatory influences is one contributor to the development and maintenance of central 
sensitization in sustained pain states (Urban and Gebhart, 1999; Porreca et al., 2002). 
From Gwaltney-Brant et al., 2000 
(TpH) 
(AADC) 
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b) Spinal and supraspinal mechanisms of pain modulation 
Based on structural (amino acid sequence), biochemical (postreceptor mechanisms 
of signal transduction) and pharmacological differences, 5-HT receptors were classified into 
7 families (5-HT1-5-HT7) and at least 14 different subtypes (Millan, 2002; Ruda et al., 1986; 
Filip and Bader, 2009). All these receptors are expressed in the brain, but some subclasses 
are also expressed within the spinal cord. Among the 14 5-HT receptor families identified so 
far, much of the pain research has focused on 5-HT1, 5-HT2 and 5-HT3 receptors, but the role 
played by other 5-HT receptors in nociception has been poorly or not thoroughly 
investigated (Colpaert, 2006; Eide and Hole, 1993; Kayser et al., 2010). Neurochemical 
findings indicate that stimulation of 5-HT1A, 5-HT1B and 5-HT1D receptors inhibits 5-HT release 
in the brain, and stimulation of 5-HT4 and 5-HT6 receptors cause an increase in the levels of 
this neurotransmitter. On the other hand, stimulation on 5-HT1A facilitates NA release in the 
brain, and stimulation on 5-HT2A and 5-HT2C inhibits the release in this neurotransmitter 
(reviewed by Filip and Bader, 2009).   
Autoradiographic studies show that among these 14 subtypes, the 5-HT1A, 5-HT1B, 5-
HT1D, and 5-HT3 binding sites are abundant in the spinal level, suggesting the presence of the 
receptors on peripheral sensory nerves. 
At the periphery, 5-HT7 receptors have been found in the superficial laminae of the 
dorsal horn, postsynaptically in local interneurons and presynaptically in peptidergic fibers 
and in astrocytes. However, it may be also present in supraspinal areas. Available data 
suggest a pro-nociceptive role of 5-HT7 receptors when activation occurs at the periphery 
(Meuser et al., 2002; Rocha-González et al., 2005). Activation of 5-HT2A and 5-HT3 receptor 
subtypes present on C-fibers was already shown to underlie such a peripheral pro-
nociceptive effect on 5-HT (Obata et al., 2000; Sommer, 2004). 
 
Electrophysiological studies have disclosed the antinociceptive mechanisms of 
descending 5-HT systems in the spinal cord level. 5-HT directly hyperpolarize SG neurons, 
inhibit the glutamate release from the Aδ and C afferent fibers, and increase GABA and 
glycine release from interneurons. Although some excitatory effects have been reported, the 
overall effect of 5-HT tends to be anti-nociceptive, in a manner similar to what occurs with 
NA (Yoshimura and Furue, 2006). 
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1.2 Type I diabetes 
 1.2.1 General Considerations 
 
Type 1 diabetes is one of the most widespread chronic illness in the world and, in 
general, is considered primarily a T-cell mediated disease arising through a complex 
interaction of immune, genetic and environmental factors, results from autoimmune 
destruction of insulin-producing ß-cells. An interplay between genetic susceptibility and 
environmental factors is thought to provide the fundamental element for disease and 
provides potential targets for both prediction and prevention of disease (Van den Driessche, 
2009; Devendra, 2004). This disease occurs most commonly in people of European 
descendent and affects 2 million people in Europe and North America (Gillespie, 2006). 
Type 1 diabetes has two types of complications: microvascular and macrovascular.  
Macrovascular complications include myocardial infarction, stroke and large vessel 
peripheral vascular disease. One of the most frequently-occuring microvascular 
complications is diabetic neuropathy (DN), that will addressed below. 
 
“STZ-rats” is a common model of type I diabetes. Streptozotocin (STZ) selectively 
destroys pancreatic islet beta-cells, similar to what occurs in type I diabetes in humans. STZ-
rats develop hyperglycemia and several complications typical of diabetes, such as diabetic 
neuropathy and retinopathy (Bhuyan et al., 1974; McCall, 1992). 
 
 1.2.2 Diabetic Neuropathy 
 
 Neuropathy is on of the most common complications associated with diabetes. It is 
characterized by sensory, autonomic and motor dysfunctions that may lead to debilitating 
clinical complications. Autonomic neuropathy is characterized by symptons ranging widely 
from minor papillary and sweating problems to significant disturbances in cardiovascular 
reflexes, alimentary, and genitourinary function (Schmidt et al, 1999). Sensory neuropathy is 
characterized by inability to perceive stimuli, such as pain and heat. Motor neuropathy is 
characterized by atrophy and weakness in muscles. Conduction velocity generally is reduced 
in sensory, motor and probably sympathetic nerves and synaptic transmission can be 
abnormal as well (Schiller and Rahamimoff, 1989). This decreased neuronal activity is 
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consistent with the reduction in brain weight and neocortical volume, which is associated 
with a reduction of the number of cortical neurons (Jakobsen et al., 1987). 
 The predominant form of DN is a symmetric polyneuropathy that is primarily 
sensory-motor and often includes the autonomic system. Patients with this disease usually 
present a reduction or loss of small fibre-mediated sensation results in loss of pain sensation 
(heat pain, pin-prick) and temperature perception to cold (Aδ) and warm (C) stimuli. Evoked 
pain such as allodynia (pain due to a stimulus that does not normally cause pain) and 
hyperalgesia (severe pain due to a stimulus that normally causes slight pain), with a distal 
and symmetrical distribution, may be present (Otto et al., 2003; Ziegler, 2008). Typically, DN 
is more severe at night, and often prevents sleep causing a constant state of tiredness 
(Quattrini et al., 2003). 
The prevalence of these neuropathies is higher in males and generally progress with 
age and duration of disease. At the time of diagnosis, neuropathy is present in 10% of 
diabetic patients but increases to 50% in patients with a 25-year history of the disease 
(Feldman et al., 1999). 
In light of current knowledge, there is little understanding about the 
pathophysiology of painful diabetic neuropathy, especially as regards to its effects on the 
CNS. Hyperglycemia is usually cause of diabetic neuropathy. It is thought to envolve the 
following pathways: activation of the polyol pathway, non-enzymatic glycosylation 
(glycation) which leads to abnormal cross-linking of proteins and altered protein function 
along with an excessive production of reactive oxygen species (Oates, 2002; Obrosova, 2002; 
Ryle and Donaghy, 1995). However, other theories suggest that some mechanisms leading to 
neuropathy may be independent of the glycemic state. Although systemic or local 
hyperglycemia in non-diabetic animals can induce mechanical hyperalgesia, impaired 
sensory and motor nerve conduction velocity and nerve blood flow, recent studies shows 
that there is a strong possibility that lack of insulin itself, resistance to its actions, or 
decresead availability of its related molecules (the insulin growth factors-IGFs), contributes 
to diabetic neuropathy. This may be explaned by the fact that both insulin and IGF1 act as 
neuronal growth factors essential for proper neuronal activity (Ishii, 1995; White, 2003). 
Therefore, the severity of diabetic neuropathy may be dependent on the combined loss of 
insulin and IGF1 activities, beyond the effects of hyperglycemia (Ishii, 1995). These ligands 
are also involved in cell survival, synaptogenesis, neurite (axon and dendrite) outgrowth and 
nerve regeneration of neurons. To strengthen this theory, it was shown that systemic IGF1 
levels in diabetic patients are slightly lower than those of nondiabetic individuals, and serum 
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IGF1 levels in diabetes patients with DN are lower than those in diabetic patients without DN 
(Guo et al., 1999; Migdalis et al., 1995). In addition, the study by Schmidt et al. (2003), 
demonstrated that type 2 diabetic rats do not develop sympathetic neuroaxonal dystrophy 
(NAD), whereas rat models of type 1 diabetes suffer from NAD. This is due to the fact that 
type 1 diabetic rats do not possess insulin, whereas type 2 diabetic rats have some insulin.  
A decline in insulin and IGF activity, as well as others neurotrophic molecules such 
neuronal growth factor (NGF) and neurotrophin 3 (NT-3) in diabetes, may lead to impaired 
production and axonal transport of tubulins and neurofilaments, diminished microtubule 
and neurofilament contents, and a dwindling of axonal diameters. Diminished axonal 
transport and/or receptor tyrosine kinase activity may contribute to the slower conduction 
velocity seen early in diabetes prior to the detection of structural alterations in axons (Ishii, 
1995). 
Intensive insulin therapy has been shown to reduce the incidence of neuropathy in a 
population of type 1 diabetic patients (DCCT Research Group, 1993). The effects of IGF1 in 
the treatment of diabetic neuropathy in humans remain unknown. 
 
1.2.2.1 Treatment 
One common comorbid psychiatric diagnosis encountered in patients with 
dysfunctional and neuropathic pain is depression. Several drugs appear to have different 
efficacy on the various symptoms and signs of diabetic neuropathic pain (Table 2).  
Table 2: Range of treatments available for neuropathic pain. 
 
 From Jensen et al., 2006 
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The drugs that are used for alleviating DN can be broadly divided into two groups: 
conventional analgesics, such as tramadol and oxycodone, and adjunctive agents, such as 
antidepressants and anticonvulsants (Chong and Hester, 2007). Several authors consider the 
tricyclic antidepressants (TCA) to be the drug treatment of choice for neuropathic pain. The 
TCAs have numerous mechanisms of action including inhibition of noradrenaline and 5-HT 
uptake from the synaptic cleft (Finnerup et al., 2005; Finnerup and Jensen, 2006; Jensen et 
al., 2006). However, their use is limited by high rates of adverse events and several 
contraindications. The light of current knowledge, antidepressants with dual selective 
inhibition of serotonin and noradrenaline (serotonin noradrenaline reuptake inhibitors-
SNRIs), such as duloxetine and vanlafaxine, proved to be the most effective for relieving the 
pain of diabetic neuropathy (Goldstein et al., 2005). These antidepressants relieve pain by 
increasing synaptic availability of noradrenaline and 5-HT in the spinal cord, which inhibit 
locally nociceptive transmission and reduce pain perception (Fig. 12) (Jensen et al., 2006). 
According to Park HJ. et al, 2010, TCAs, gabapentin and pregabalin are 
recommended to be the first-line treatment options for patients with neuropathic pain, 
whereas opioid analgesics should be reserved as second or third-line options in most cases. 
 
 
 
Fig. 12: General principles of pharmacotherapy for DN. 
 
 
 
 
 
From Jensen et al., 2006 
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 1.2.3 Neurochemistry and pharmacology 
1.2.3.1 The Insulin/IGF system 
Insulin, insulin-like growth factor 1 (IGF1) and insulin-like growth factor 2 (IGF2) are 
three closely polypeptide hormones with amino acid sequences considerably homologous 
that mediate a variety of metabolic and mitogenic effects by binding to their specific 
receptor tyrosine kinases present on the surface of target tissues and cells (Joan and 
Michael, 1981; Ursula et al., 2009). Insulin is synthesized predominantly in pancreatic beta 
cells from which its release is regulated by nutrient stimuli. IGF1 is synthetized by the liver 
upon stimulation by pituitary growth hormone (GH). It is also synthesized locally in many 
tissues, including the brain (Bondy and Cheng, 2004). 
Because of the considerable structural homology of insulin and IGF1 receptors, a 
distinct overlap exists in binding affinity between insulin and IGFs (Fig. 13). Although some 
studies have indicated that the IGF-binding sites in some tissues exhibit a certain degree of 
affinity for insulin, and the high affinity insulin receptor specifically interacts with IGF1 and 
IGF2 (Zapf, 1978), at physiological concentrations, insulin and IGF1 exclusively bind to their 
cognate receptors (Ursula et al., 2009). Differences in kinetics of ligand binding and receptor 
activation by the insulin and IGF1 receptors may be one of the factors determining their 
specificity (Shymko et al., 1997).  
There are three separate receptors that can bind insulin and the IGFs: insulin 
receptor (IR) (Ullrich et al, 1985; Ebina et al, 1985), IGF1 receptor (IGF1R) (Ullrich et al, 1986) 
and IGF2 receptor (IGF2R) (Morgan et al, 1987). A fourth, orphan member of the family is 
insulin receptor-related receptor (IRR), that it is thought to mediate the action of a ligand(s) 
identical or very similar to insulin, IGF1 or IGF2 (Fig. 14) (Shier and Watt, 1989). In addition 
to IGF1R and IGF2R, the IGF system includes 6 IGF-binding proteins (IGFBP1 to IGFBP6), 
which in addition to their main role as carriers of IGF1 and IGF2 in the circulation, also 
regulate the biological actions of IGFs either by inhibiting or potentiating their binding to cell 
surface receptors (Baserga et al., 1999).  
Insulin and type I IGF receptors are structurally similar, both being comprised of α2ß2 
heterotetramers. Like the insulin receptor, the IGF1 receptor is a membrane glycoprotein of 
Mr 300000-350000, consisting of two α-subunits (Mr~135000), that contains the 
extracellular ligand binding domain, and two ß-subunits (Mr~90000) that are connected by 
disulfide bonds to form the functional ß-α-α-ß heterotetrameric receptor complex 
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(Massague and Czech, 1982; Kull et al., 1983). The intracellular domain of the membrane-
spanning ß-subunits contains a tyrosine kinase consensus sequence that can be activated by 
ligand and binding. The type II IGF receptor is comprised of a single polypeptide that does 
not have a tyrosine kinase domain (Ishii, 1995). Ligand binding triggers a conformational 
change that enables the receptors to bind ATP. Autophosphorylation increases their kinase 
activity and catalyses substrate phosphorylation to engender growth or metabolic 
responses. 
 
 
 
 
Fig. 13: Structural homology between insulin and IGF1 receptors.  
 
 
Despite the functional and structural similarities, these two hormones are thought to 
play different biological roles during mammalian development and mature life. Whereas 
insulin plays a key role in regulation of a variety of metabolic processes, the IGFs appear to 
be more potent in regulation of cellular growth and differentiation. This is consistent with 
the fact that both IGF1 and IGF2 are expressed in various embryonic and adult tissues 
(Ullrich et al., 1986; Shin et al., 1994). 
 Autoradiographic studies reveal the widespread distribution of insulin, type I IGF and 
type II IGF receptors throughout the brain, suggesting a role in the CNS (Bondy et al., 1992). 
 
 
 
 
From “Bondy and Cheng, 2004” 
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From Kitamura et al, 2003 
Fig. 14: Interactions among ligands and receptors of the insulin family.  
 
The decline in the levels of growth factors necessary for peripheral nerve function 
has been postulated as one of the metabolic alterations that originate nerve dysfunction and 
subsequently diabetic neuropathy (Kamiya et al., 2006). In particular, decreased IGF1 levels 
have been postulated as a possible cause of neurological disorders in diabetes (Guo et al., 
1999). 
 
1.2.3.2 Noradrenaline and serotonin 
 
Studies with STZ-rats showed that type I diabetes induces changes in the 
neurotransmitter content of brainstem, but the results are not consistent.  In the study 
made by Padayatti and Paulose (1999), the STZ rats was shown an increase in 5-HT content 
in brainstem of diabetic rats, that was associated with a reduced affinity for serotonergic 
receptors. The insulin treatment with doses that do not reverse hyperglycemia reversed that 
parameter. On the other hand, in the same study, the NA content in diabetic brainstem was 
not affected. This last result is not, however, concensual since other study has shown that 
there is a reduction in noradrenergic neuronal activity in diabetic neuropathy, with a 
reduction in noradrenaline synthesis, associated with a difficulty to release this 
neurotransmitter from synaptic terminal. In the study led by Gallego et al (2003), diabetes 
altered NA levels in the sympathetic nervous system but not in large regions of the brain 
(medulla, pons, midbrain and striatum) of diabetic rats. 
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Chapter 2: Aims 
 
The effects of diabetic neuropathy have been widely studied at the periphery but its 
central causes remain understudied. Since several studies support the hypothesis that 
deficiencies in insulin and/or IGF1 signaling may play an important role in the development 
of diabetic neuropathy in diabetes type I, independently of glycemic condition, we designed 
an experimental protocol to evaluate the effects of insulin and IGF1 treatment of a rat model 
of type I diabetes (the STZ-diabetic rat) in a paradigm that does not revert the hyperglycemic 
state of the animals. The main objectives of this study were to evaluate the effects of low 
doses of insulin and IGF1 in: 
1) Pain behavioral responses. The pain behavioral responses will be assessed using the 
Randall-Selitto test, that measures mechanical hyperalgesia, and the formalin test, that is a 
widely employed mean to measure responses to a persistent noxious stimulus.  
2) Neuronal activity at spinal cord and PAG, using c-fos expression to monitor neuronal 
activation. Fos is a nuclear protein encoded by the proto-oncogene c-fos, which is visualised 
by immunocytochemical techniques. Fos protein levels increase in the brain and spinal cord, 
in response to various types of noxious stimuli. c-fos expression is currently used to study 
nociception and has been employed as a functional marker of nociceptive activation of large 
neuronal populations (Harris, 1998). 
3) The expression of NA and 5-HT in brainstem areas that project directly to the spinal 
cord and are involved in pain modulation. The numbers of noradrenergic neurons in the A5, 
A6 and A7 cell groups of the brainstem were counted after immunostaining for TH. As to 5-
HT, the numbers of serotoninergic neurons were quantified at the RVM after 
immunostaining for TpH. The spinal levels of NA and 5-HT were quantified using 
appropriated ELISA kits. 
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Chapter 3: Material and Methods 
 
 
1. Drugs  
Streptozotocin was purchased from Sigma–Aldrich (St. Louis, USA); insulin was 
purchased from Sanofi Aventis and IGF1 was offered by Ipsen Portugal. 
2. Animals 
A total of 40 male Wistar rats (Charles River Laboratories, Barcelona, Spain), 
weighing 300–350 g at the beginning of the experiments, were used. The experiments were 
performed in accordance with the ethical guidelines of the European Community Council 
Directive 86/609/EEC and the ethical guidelines for the study of pain in conscious animals 
(Zimmermann, 1983).  
Animals were housed two per cage, in a room with a constant temperature (22 ± 2 
◦C) and humidity (55 ± 5%) and with a 12-h light/dark cycle, and received food and water ad 
libitum. 
3. Induction of diabetes 
Experiments started 1 week after the rats were fully adapted to their environment. 
Diabetes was induced by an intraperitoneal (i.p.) injection of STZ (60 mg/kg body weight) 
dissolved in citrate buffer (pH = 4.5) (STZ group; n = 30). Controls received equal volumes of 
citrate buffer (pH = 4.5) (control group; n = 10). Three days after the injection, glucose 
concentration was measured in tail vein blood samples using a glucose oxidase impregnated 
test strip (Accu Chek Sensor Comfort, Roche Diagnostics, Germany). Only rats with glucose 
concentration higher than 270 mg/dl were considered diabetic and included in the study. All 
animals were monitored daily and weighed regularly during the study period. 
 
 
4. Treatment 
The treatment protocol is summarized in Figure 15. 
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Fig. 15: Schematic overview of the experimental protocol. R.S. - Randall-Selitto; F.T. - 
Formalin Test. 
 
Diabetes was induced in day 0 and afterwards, the diabetic rats were divided into 
three subgroups: treated with insulin (STZ + INS; n = 10), treated with IGF1 (STZ + IGF1; n = 
10), and injected with vehicle (STZ + saline; n = 10).  
Mechanical nociception was assessed for the first time on day 0. On day 7, 
treatment of various STZ groups started. Diabetic rats were subcutaneously injected 3 times 
per week during 3 weeks with 2 IU of insulin, 2,5 mg/Kg of IGF1, and 300 µl of saline. Control 
rats received an equivalent volume of vehicle. The injections were performed always at the 
same time of the day. 
All rats were weekly tested for evaluation of mechanical  
nociception during the 4 weeks of the study, using the Randall Selitto test (see “Behavioral 
tests”). Blood glucose concentration was also assessed, immediately before the injection of 
insulin, the IGF1 or saline to confirm, if the hyperglycemia was maintained in diabetic rats, in 
spite of the treatment protocols.      
 
 
 
  
MSc Thesis                                                                     Central effects of insulin and IGF1 in diabetic neuropathy 
 
Liliana Silva                                                                    27 
 
5. Behavioral tests 
After i.p injection, all animals were evaluated once a week to confirm the existence 
of behavioral signs of diabetic neuropathy in diabetic rats, using the Randall-Selitto test (Fig. 
14). 
All animals were habituated to handling and testing environment before the 
behavioral evaluation was started. 
   5.1 Randall-Selitto test: 
Mechanical nociceptive thresholds were quantified by means of an Analgesymeter 
(Ugo-Basile, Comerio, Italy). All animals were subjected to a time-course behavioural 
evaluation of mechanical nociception, at 1, 2, 3 and 4 weeks after STZ or saline injection. An 
increasing pressure was applied on the dorsal area of the hindpaw with a cone-shaped 
plunger. The nociceptive threshold was defined as the force, in grams, at which the rat 
attempted to withdraw the paw, vocalized or struggled. The mechanical threshold of each 
animal was the average of three consecutive measurements, taken at 5-min intervals. 
 
 
Fig. 16: Photograph of a rat in the Randall-Selitto test. 
 
 5.2 Formalin-evoked flinching: 
Four weeks after of diabetes induction, all groups of animals (n = 5 per group) were 
singly housed in Perspex boxes (Fig. 17) and given 60 min to habituate to the testing 
environment. Animals were then injected sub-dermally, into the right hindpaw dorsum, with 
http://www.fmigmbh.de/PIX/content/TN160/uba-37215.jpg 
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50 µl of 0.2 % formalin. Flinching behaviors were counted in successive periods of 5-min 
during 60 min (Zhao et al., 2006; Ceseña and Calcutt, 1999). 
 
 
Photo kindly provided by José Lopes 
Fig. 17: Photograph of three rats in Perspex boxes during the formalin test. 
 
6. Harvesting of biological material 
Two hours after formalin injection, animals from each experimental group were 
sacrificed by transcardiac perfusion to perform the immunohistochemistry for c-fos 
expression at the spinal cord and PAG and for TH (noradrenergic marker) and TpH 
(serotoninergic marker) in the brainstem. The perfusions were performed after anaesthesia 
with an i.p. injection of 35% chloral hydrate (1ml/kg body weight). Vascular perfusion was 
performed with 200 ml of phosphate-buffered saline (PBS), followed by 1000 ml of 4% 
paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4 (Fig. 18 A-C).  
Spinal segments L4-L5 (which receive input from the injected paw; Grant and 
Robertson, 2004), and the brainstem were removed, post-fixed for 2–4 h in the same 
fixative, and cryoprotected overnight in 30% sucrose in 0.1 M PBS, at 4ºC (Fig. 18 D-E). 
Coronal sections, 40 µm thick, were obtained using a freezing microtome, and every fourth 
section was collected in 0.1 M PBS. 
One additional set of animals (n=5 per group) were sacrificed by decapitation and 
the lumbar spinal segments (L4-L5) were removed immediately. Then, the dissected tissue 
samples were stored at -80ºC until analysis with ELISA kits, for noradrenaline and 5-HT 
quantification. 
 
  
MSc Thesis                                                                     Central effects of insulin and IGF1 in diabetic neuropathy 
 
Liliana Silva                                                                    29
 
 
                    Photos kindly provided by Diana Nascimento 
 
Fig. 18: Sequential pictures that represent some of the steps performed during the 
transcardiac perfusion. A - The anesthetized rat were placed in a cork board where they 
underwent the perfusion; B - With the aid of forceps and scissors, cut up the chest by the 
diaphragm; C - The excess blood was removed by passing a washing solution (Tyrode) in the 
cardiovascular tissue of the rat. D - Dissection of the brain is done carefully with the help of a 
gouge suitable for this purpose; E and F - The ganglia and the spinal cord were removed from 
the remaining tissue of the animal. 
7. Immunocytochemistry  
     7.1 Processing of spinal cord and PAG section for c-fos Evaluation 
Fos protein was immunohistochemically detected by the avidin - biotin - peroxidase 
method, using the compound 3,3´-diaminobenzidine (DAB) as chromogen, as described 
previously (Morgado and Tavares, 2007; Morgado et al., 2009). Briefly, the sections were 
treated with 1% hydrogen peroxidase for 10 min to inhibit endogenous peroxidase activity. 
In order to decrease background staining, incubation in primary antibody was 
preceeded by immersion the sections in a blocking solution of 10% normal swine serum 
(NSS, serum produced in the animal species from which the respective secondary antibody 
was obtained) in 0.3% Triton X 100 in PBS (PBST) with 0.1 M glycine for 2 h. 
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 The sections were then incubated during two overnights at 4 ºC in rabbit polyclonal 
anti-Fos (Ab5; Oncogene; Germany), diluted at 1:5,000 in PBST. After being washed in PBST 
plus 2% NSS, the sections were incubated in biotinylated swine anti-rabbit immunoglobulin 
(Dako, Denmark), diluted at 1:200, for 1 h, at room temperature. The sections were then 
washed in PBST, incubated for 1 h in the avidin-biotin complex at room temperature 
(Vectastain, Vector Laboratories, USA) followed by a mixture of 10 mg diaminobenzidine, 5 
µl of 30% hydrogen peroxide in 20 ml of Tris-HCl 0.05 M, pH 7.6. All sections were mounted 
on gelatin-coated slides. The numbers of Fos-immunoreactive (Fos-IR) cells occurring 
ipsilateral to the stimulated hindlimb in laminae I–II (superficial dorsal horn) and III–V (deep 
dorsal horn) were counted in 10 spinal sections. Laminae delimitation was performed 
according to Paxinos and Watson, 2005, as described previously (Morgado and Tavares, 
2007). The numbers of Fos-IR cells occurring in all sections of dorsal lateral PAG (VLPAG) 
were also counted, according to Paxinos and Watson, 2005.  
 
   7.2 Processing of brainstem sections for Tyrosine Hydroxilase (TH) and Tryptofan 
Hydroxylase (TpH) Evaluation 
TH and TpH were immunohistochemically detected by the avidin - biotin - 
peroxidase method, using the compound 3,3´-diaminobenzidine (DAB) as chromogen. 
Sections were treated with 1% hydrogen peroxidase for 10 min to inhibit endogenous 
peroxidase activity. 
In order to decrease background staining, incubation in primary antibody was 
preceded by immersion sections in a blocking solution of 10% normal swine serum (NSS) and 
10% normal horse serum (NHS), respectively, in 0.3% Triton X 100 in PBS (PBST) with 0.1 M 
glycine for 2 h. Those sera were produced in the animal species from which the respective 
secondary antibody was obtained.  
The sections were then incubated during two overnights at 4 ºC in the primary 
antibody, rabbit anti-TH (Affinity BioReagents) and sheep anti-TpH (AB1541; Millipore; 
Temecula California), diluted at 1:6,000 and 1:1,000 in PBST. Although this last antiserum 
has some cross-reactivity to tyrosine hydroxylase, which is present in some adrenergic 
neurons, it was selected for its very high sensitivity for TpH. After being washed in PBST plus 
2% NSS or NHS, the sections were incubated in biotinylated swine anti-rabbit 
immunoglobulin (Dako, Denmark) and in biotinylated donkey anti-sheep (Sigma, Germany), 
diluted at 1:200, for 1 h, at room temperature. The sections were then washed in PBST, 
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incubated for 1 h in the avidin–biotin complex at room temperature (Vectastain, Vector 
Laboratories, USA) followed by the diaminobenzidine, mixture described above. All sections 
were mounted on gelatin-coated slides. The numbers of TH-immunoreactive (TH-IR) cells 
were counted in A5 noradrenergic cell group of the pons and in the A7 noradrenergic cell 
group of the mesencephalon. Densitometric analysis was performed in the A6 noradrenergic 
cell group of the pons, using NIH Image 1.52 software (US National Institutes of Health). The 
numbers of TpH-immunoreactive (TpH-IR) cells were counted in the RVM. 
 
The Image acquisition was performed with a Axioskop 40 confocal system, using a 
10x lens. 
All sections were processed simultaneously in order to minimize differences in 
staining intensity due to daily variations in the method. To test the specificity of the 
antibodies used, negative controls were performed by omission primary antibody or 
replacing this by a normal serum. 
 
8. ELISA 
To quantify spinal noradrenaline and serotonin levels, the lumbar spinal segments 
L4-L5 were homogenized and processed by ELISA kits commercially avaiable (BA E-5200 and 
BA E-5900 “Labor Diagnostika Nord”, for Noradrenaline and Serotonin quantification, 
respectively. The processing of the samples was carried out following the manufacturer’s 
recommended procedures. 
 
9. Analysis of data 
Data were compared by One-Way Analysis of Variance (ANOVA) followed by LSD  
Fisher post-hoc test for multiple comparisons. Time-course analysis of  
behavioral data was compared by ANOVA repeated measures for each  
experimental group. Statistical significance was settled as p<0,05.  
Results are presented as mean ± SEM. 
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Chapter 4: Results 
 
1. Glycemia and Body Weights (BW) 
Three days after STZ injection, the rats developed hyperglycemia (blood glucose 
concentration > 270 mg/dl) which remained during all the experimental period, 
independently of the treatment protocol. 
A gradual decrease in BW was observed in saline-treated STZ rats. Insulin and IGF1 
treatment prevented this weight loss (statistically significant in the 4
rd
 week of diabetes), but 
did not restore BW to values of non-diabetic control rats (Fig. 19). In the last week of the 
study, STZ rats present a body weight of 248±9.36 g; control group present 388±8.02 g, 
STZ+Ins rats present 283±7.06 g and STZ+IGF1 present 278±7.87 g. 
 
 
Fig. 19: Effects of insulin and IGF1 on body weight. Significance of symbols: # - comparison 
between controls and all other experimental groups; * - comparison between STZ+saline and 
STZ+Ins or STZ+IGF1. One symbol: p<0,05; two symbols: p<0,01. 
 
2. Behavioral tests 
   2.1 Randall-Selitto test: 
 
Saline-treated STZ rats exhibit mechanical hyperalgesia beginning at 1 week post-
injection which aggravates with diabetes progression. This is consistent with the painful 
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neuropathic condition and agrees with previous studies in this rat strain (Morgado et al., 
2007). Insulin and IGF1 treatments prevented the aggravation of mechanical hyperalgesia.  
This is particularly evident at 2, 3 and 4 weeks of diabetes, when the nociceptive thresholds 
for treated animals are significantly higher when compared with STZ rats and the respective 
behavioral response (Fig. 20). 
 
 
 
Fig. 20: Time-course changes of mechanical response thresholds in control and treated rats. 
Significance of symbols: # - comparison between controls and all other experimental groups; 
* - comparison between STZ+saline versus STZ+Ins and STZ+IGF1. One symbol: p<0,05; two 
symbols: p<0,01. 
 
 2.2 Formalin-evoked flinching 
Four weeks after diabetes induction, untreated STZ rats that were injected with 0.2% 
formalin solution show a higher frequency of flinching behavior (116.4±29.5) compared to 
controls (44.9±11.9), during the 60-min observation period. This chemical allodynic response 
of diabetic rats to formalin was prevented by treatment with insulin (48.6±11.3) or IGF1 
(47.6±6.8) (Fig. 21). 
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Fig. 21: Sum of flinches measured during 60 minutes, after injection of 0.2% formalin into 
the hindpaw of control rats (white bars), non-treated STZ rats (black bars), STZ rats treated 
with insulin (dark gray bars), and STZ rats treated with IGF1 (light gray bars). N = 5 per group. 
Data are group mean ± SEM. Significance of symbols: * - comparison between STZ+saline 
and all other experimental groups (p<0,01). 
 
3. Spinal and PAG evaluation of c-fos expression 
c-Fos, an immediate early gene protein product, is a neuroactive marker that can be 
used to analyse nociceptive pathways (Curran and Morgan, 1995; Vergnolle et al., 2001; 
Watkins et al., 1997). We compared c-Fos expression between controls, saline and insulin- or 
IGF1- treated rats (n=5/group). c-Fos-immunoreactivity (Fos-IR) was evaluated in the 
superficial (I-II) and deep laminae (III-V) of the spinal dorsal horn. Since no differences in the 
results of the superficial and deep laminae were encountered, the countings are presented 
together (Fig. 22 A).  As illustrated in Fig. 22 A, the numbers of c-Fos-positive cells in 
ipsilateral L4-L5 were higher in untreated STZ rats (STZ+saline) than in the other 
experimental groups (STZ+saline: 104.9±28.2 versus Control: 18.6±28.2; STZ+Ins: 24.9±28.2 
and STZ+IGF1: 30.5±6.3). In Fig. 22 B, the number of c-Fos-positive cells in VLPAG was also 
higher in untreated STZ rats (STZ+saline) than the other experimental groups (STZ+saline: 
278.9±16.8 versus Control: 107.8±23.5; STZ+Ins: 58.3±27.3 and STZ+IGF1: 45.6±13.9). These 
differences between untreated STZ rats and the other groups were statistically significant 
(p<0,01). 
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Fig. 22: Mean numbers of Fos-IR neurons (±SEM) counted bilaterally in laminae I-V of the L4-
L5 spinal segments (A) and in VLPAG (B). Significance of symbols: ** - comparison between 
STZ+saline and all other experimental groups (p<0,01). 
          
          
Fig. 23: A-D: Photomicrographs of Fos labeled neurons in L4-L5 spinal segments of control 
rats (A), STZ+saline (B), STZ+Ins (C) and STZ+IGF1 (D) treated rats. Scale bar in D: 100 µm (all 
photographs are at the same magnification). 
 
A B 
100 µm 
D C 
B A 
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Fig. 24: A-D: Photomicrographs of Fos labeled neurons in VLPAG of control rats (A), 
STZ+saline (B), STZ+Ins (C) and STZ+IGF1 (D) treated rats. Scale bar in D: 100 µm (all 
photographs are at the same magnification). 
 
4. Tyrosine Hydroxilase (TH) Evaluation 
The numbers of noradrenergic neurons of the A5, A6 and A7 were counted by their 
immunoreactivity to tyrosine hydroxilase (TH-IR).  In contrast to the neurons of A6 and A7, 
that not display statistically differences between groups, in A5 noradrenergic cell group, a 
significant increase in the numbers of TH-IR neurons was detected in saline-injected STZ rats 
(27.5±2.42) and insulin treated-rats (27.1±1.64), when compared with control animals 
(22.1±1.3). As shown in Fig. 25 A, in the A5 cell goup, IGF1 prevented the increase in TH-IR 
neurons, while insulin had no effect (20.4±1.57 and 27.1±1.64, respectively). 
Fig. 26 A-D illustrates representative example of noradrenergic neurons of the A5 
cell group that were characterized by the presence of tyrosine-hydroxylase 
immunoreactivity of the neurons. As can be seen in the images, the noradrenergic A5 cell 
100 µm 
C D 
A B 
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groups of rats treated with IGF1, show a decrease in TH-IR neurons, which was similar to 
controls. 
In what concerns the Noradrenaline content at lumbar spinal cord, there was a 
statistically significant difference between STZ-saline (6.15±0.34) versus control (4.72±0.16) 
and STZ+IGF1 (4.32±0.49) group. As in the A5 cell group, also in lumbar spinal cord STZ-
diabetic rats presented increased levels of noradrenaline. IGF1 treatment diminished this 
level to values similar to controls, while insulin had no effect (5.45±0.30) (Fig. 25 B).  
 
 
 
 
 
 
Fig. 25 A: Numbers of TH-IR in A5 and A7 noradrenergic cell groups, and labeling density in 
the A6 noradrenergic cell group. Significance of symbols: * - comparison between STZ+saline 
versus control and STZ+IGF1. # - comparison between STZ+Ins versus STZ+IGF1 (p<0,05).  
B: Noradrenaline content at lumbar spinal cord. Significance of symbols: * - comparison 
between STZ+saline versus control and STZ+IGF1. # - comparison between STZ+Ins versus 
STZ+IGF1. One symbol: p<0,05; two symbols: p<0,01. 
A 
B 
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Fig. 26: A-D: Representative example of noradrenergic neurons of the A5 cell group that 
were characterized by the presence of tyrosine-hydroxylase immunoreactivity of the 
neurons. Scale bar in D: 100 µm (all photographs are at the same magnification). 
 
5. Tryptofan Hydroxylase (TpH) Evaluation 
The total number of serotoninergic neurons of the RVM was counted by their 
immunoreactivity to tryptofan hydroxylase (TpH-IR). STZ-saline injected-rats display a 
significant increase in the numbers of TpH-IR neurons (28.8±8.9), when compared with 
control animals (3.8±1.7) and IGF1 treated rats (5.06±1.4) (Fig. 27 A). The treatment with 
insulin had no effect, with values very similar to those of untreated diabetic rats (27.5±9.1 
versus 28.8±8.9, respectively). 
In what concerns the Serotonin levels at the lumbar spinal cord (Fig. 27 B), there was 
a statistically significant difference between STZ-saline (0.5±0.08) versus control (0.23±0.04) 
and STZ+IGF1 (0.17±0.02) group. Once again, insulin had no effect (0.35±0.1), with values 
similar to those of untreated diabetic rats. 
100 µm 
A B 
C D 
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Fig. 28 A-D illustrates representative examples of serotoninergic neurons of the RVM 
in the different experimental group. As can be seen in these images, rats treated with IGF1, 
show a decrease in TpH-IR neurons, similar to controls. 
 
 
                  
 
Fig. 27 A: Number of serotoninergic neurons of the RVM by their immunoreactivity to 
tryptofan hydroxylase (TpH-IR).  Significance of symbols: * - comparison between STZ+saline 
versus controls and IGF1 treated rats; # - comparison between control versus saline and 
insulin treated rats. B: Serotonin content at lumbar spinal cord. Significance of symbols: * - 
comparison between STZ+saline versus control and STZ+IGF1 treated rats. One symbol: 
p<0,05; two symbols: p<0,01. 
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Fig. 28: A-D: representative example of serotoninergic neurons in the RVM that were 
characterized by the presence of tryptofan-hydroxylase immunoreactivity of the neurons. 
Scale bar in D: 100 µm (all photographs are at the same magnification). 
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Chapter 5: Discussion 
 
 In the current literature, very little is known about the pathophysiology of diabetic 
neuropathy, especially as regards to its effects on the CNS. Hyperglycemia is usually 
considered the major agent of diabetic neuropathy and is already known that, by itself, it is 
capable to alter neurons, axons, and Schwann cells through one of several mechanisms that 
include excessive polyol flux (Greene DA., 1987), myoinositol depletation (Greene DA., 
1992), alterations in protein kinase C isoforms (Roberts RE., 1997; Nakamura J., 1999 and 
Yamagishi S., 2001), glycosylation of structural nerve proteins such as tubulin or 
neurofilament (Ryle C., 1995 and Cullum NA., 1991), oxidative stress triggered by glucose 
auto-oxidation, or nerve and ganglion microvascular ischemia (Low PA., 1997).  However, 
currently new studies are emerging to assess the role of other factores in addition to 
hyperglycemia per se. 
The overall goal of these studies was to evaluate the efficacy, in CNS, of systemic 
administration of low doses of insulin and IGF1 in abrogating the neuropathy symptons 
typically associated with type 1 diabetes. For this purpose, we used a common model of rats 
(called “STZ-rats”), that develop diabetes by injection with Streptozotocin.   
The treatment with low doses of insulin or IGF1 did not interfere with the 
hyperglycaemic condition of STZ-diabetic rats. The analgesic effects of treatment with low 
doses of insulin agrees with previous reports (Hoybergs and Meert, 2007) and shows that 
the effects of insulin in diabetic neuropathy may be independent of the hyperglycaemic 
condition. 
 
Noradrenergic and serotoninergic modulation of nociceptive transmission in STZ rats 
The present study shows, for the first time, alterations of noradrenergic and 
serotoninergic innervation of the spinal cord in STZ-diabetic rats. Increased numbers of TH-IR 
and TpH-IR neurons are considered an indication of increased levels of noradrenaline and 
serotonin, respectively. Our ELISA results further show that both noradrenaline and 
serotonin are increased at the spinal cord. These results are in accordance with the study 
lead by Bitar MD. 1999, in which the spinal contents of NA in male and female rats were 
increased over their corresponding control values. Curiously, STZ-diabetic rats have 
mechanical hyperalgesia and chemical allodynia, demonstrated by the increased behavioral 
responses in the Randall-Sellito and formalin tests, respectively. This, along with the 
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increased nociceptive responses of spinal neurons, demonstrated by the higher Fos-
expression after formalin injection (present results) and without noxious stimulation 
(Morgado et al., 2007), indicates that the increased descending modulation by noradrenaline 
and serotonin does not lead to antinociception. This may be explained by alterations in the 
mechanisms of monoaminergic degradation at the spinal cord in STZ-diabetic rats or by 
increased action of excitatory effects of noradrenaline and serotonin, due to actions on 
receptors involved in facilitation of nociceptive transmission. The study leads by Bitar MD. 
1999, demonstrated a decrease in the number of α2-adrenoceptor binding sites and α2-
adrenoceptor mRNA expression in the spinal cord of STZ-diabetic rats, which may indicate 
that, in this disease, noradrenaline is not acting properly in their receptors. Furthermore, in 
2000, this same author showed that some features of diabetic neuropathic pain involve an 
aberration in lumbospinal α2-adrenoceptors. This hypoactivity of noradrenergic system in 
diabetic states is not limited to the lumbar segment of the spinal cord but extends to other 
areas of the brain including the hypothalamus, hippocampus and brainstem. 
As to the mechanisms that may explain the increased levels of noradrenaline and serotonin 
at the A5 noradrenergic cell group and RVM, respectively, in STZ-diabetic rats, several 
possibilities may be defined. They may represent a reaction to the chronic pain condition 
since it was already demonstrated that in chronic traumatic pain, the levels of TH increase in 
the locus coeruleus and spinal cord (Ma and Eisenach, 2005). They may also be due to 
specific molecular events induced by diabetes itself in neurons of the A5 and RVM. Ongoing 
studies are planned to ascertain the molecular mechanisms involved which may be related 
to specific deficits of insulin and IGF1 in this type of diabetes.  
 
Role of insulin and IGF1 in noradrenergic and serotoninergic modulation in STZ-
diabetic rats 
The present study shows that IGF1 reverses the signs of diabetic neuropathy and, 
concomitantly, normalizes the increased levels of noradrenaline and serotonin in the 
brainstem. It should be recalled the improvement in the behavioral signs of diabetic 
neuropathy after IGF1 treatment were previously described but they were ascribed to 
effects of IGF1 at the periphery (Nunez et al., 2010). By demonstrating beneficial effects of 
IGF1 in noradrenaline and serotonin expression in pain control centres of the brainstem, our 
results show that central actions should also be considered after IGF1 treatment. IGF1 
receptors are present in brainstem areas were the effects of IGF1 were maximal, namely the 
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pontine A5 noradrenergic cell group and the RVM. This further supports a specific effect of 
the disease in brainstem neurons, probably due to deficits of IGF1 during type 1 diabetes. 
The treatment with low doses of insulin did not interfere with the hyperglycaemic condition 
of STZ-diabetic rats. The analgesic effects of treatment with low doses of insulin agrees with 
previous reports (Hoybergs and Meert, 2007) and shows that the effects of insulin in diabetic 
neuropathy may be independent of the hyperglycaemic condition. In spite of the 
improvement of behavioral responses of STZ-diabetic rats and nociceptive activation of 
spinal neurons after insulin treatment, it did not alter the levels of noradrenaline and 
serotonin in the brainstem and spinal cord. This indicates that the antinociceptive effects of 
insulin treatment are not mediated by the noradrenergic and serotoninergic brainstem areas 
under study. It cannot, however, be discarded that insulin has central effects, acting on 
hypothalamus, limbic system, cerebral cortex and olfactory bulb (Unger et al., 1989). Besides 
that, peripheral neurotrophic effects of insulin are also to be considered. 
In summary, the present results showing that treatment with low doses of insulin has 
analgesic effects, suggest the importance of an effective and early insulin therapy in type 1 
diabetes. On the other hand, IGF1 had also antinociceptive effects, probably mediated by 
controlling the mechanisms of noradrenergic and serotoninergic modulation of nociceptive 
transmission at the spinal cord. A combination of insulin and IGF1 therapies could provide a 
valuable approach for pain control during diabetic neuropathy. 
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Chapter 6: Final Conclusion and Future Perspectives 
 
The present master thesis evaluated, for the first time, important aspects of the role 
of IGF1 as a neurotrophic factor in diabetic neuropathy, showing important effects at the 
central nervous system. Although the current data cannot be directly extrapolated to human 
health, they demand to be explored in the future namely in what concerns possible 
consequences of a longer treatment with IGF1. IGF1 has been used in the treatment of other 
disorders, namely in what concerns growth delays in children, without the evidence of major 
secondary effects. This indicates that the treatment of diabetic patients with IGF1 will 
probably be safe. Since type 1 diabetic patients are treated with insulin, it will be important 
to evaluate the effects of the association of insulin and IGF1 in experimental models. In fact, 
intensive insulin treatment may potentially ameliorate neuropathy at least in part because 
of the partial restoration of IGF activity (Ishii DN., 1995). Nevertheless, IGFs might also then 
be used in replacement therapy to ameliorate or prevent the progression of neuropathy or 
possibly reverse it in the early stages (Ishii DN., 1995). 
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Chapter 7: Publications with data from this Master Thesis 
 
The work carried out under the subject of this Master Thesis was 
published/submitted as following:  
 
Posters in Conferences:  
 
•  Silva L., Morgado C., Pereira-Terra P. and Tavares I. Mechanical hyperalgesia in 
Streptozotocin-diabetic rats is partially prevented with low doses of insulin or IGF1 without 
a reversion of the hyperglycemic condition. 11th Meeting of the Portuguese Society for 
Neuroscience, Braga, June 3-6, 2009. 
 
•  Silva L., Morgado C., Pereira-Terra P. and Tavares I. Administration of low doses of insulin 
and IGF-1 improves painful diabetic neuropathy in streptozotocin-diabetic rats. 6
th
 
Congress of the European Federation of IASP
®
 Chapters (EFIC), Lisbon, September 9-12, 
2009. 
 
• Patrícia Pereira-Terra, Liliana Silva, Carla Morgado, Isaura Tavares. Insulin Growth Factor 1 
ameliorates formalin-induced pain and prevents neuronal hyperactivity at spinal cord and 
periaqueductal grey during painful diabetic neuropathy. I3S Meeting, Póvoa do Varzim, 
May 6-7, 2010. 
 
• Patrícia Pereira-Terra, Liliana Silva, Carla Morgado, Isaura Tavares. IGF-1 prevents the 
effects of diabetic neuropathy on noradrenergic neurons involved in descending pain 
modulation. 7
th
 FENS Forum of European Neuroscience, Amsterdam, July 3-7, 2010.  
 
 
Papers in conference proceedings:  
 
• Silva L., Morgado C., Pereira-Terra P. and Tavares I. Mechanical hyperalgesia in 
Streptozotocin-diabetic rats is partially prevented with low doses of insulin or IGF-1 
without a reversion of the hyperglycemic condition. Abstractbook of 11th Meeting of the 
Portuguese Society for Neuroscience, 3-6 June, 2009. 
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• Silva L., Morgado C., Pereira-Terra P. and Tavares I. Mechanical hyperalgesia in 
Streptozotocin-diabetic rats is partially prevented with low doses of insulin or IGF-1 
without a reversion of the hyperglycemic condition. Frontiers in Neuroscience (Conference 
Abstract: 11th Meeting of the Portuguese Society for Neuroscience. doi: 
10.3389/conf.neuro.01.2009.11.121). 
 
• Silva L., Morgado C., Pereira-Terra P. and Tavares I. Administration of low doses of insulin 
and IGF-1 improves painful diabetic neuropathy in streptozotocin-diabetic rats. European 
Journal of Pain (official journal of the European Federation of Chapters of the International 
Association for the Study of Pain
®
 - EFIC), September 2009, Vol.13, No.8, page S169. 
 
 
Papers:  
 
• Morgado C., Silva L., Pereira-Terra P. and Tavares I. Painful diabetic neuropathy affects 
serotoninergic and noradrenergic innervations of the spinal cord due to changes in 
descending nociceptive modulation. Manuscript submitted to “Neurobiology of disease”. 
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